Evidence map›Paper›PMID 28881779›Full record

ArticleOncotarget2017

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.

Lingfei Wang, Xiaojie Yu, Chao Wang, Shujun Pan, Beibei Liang, Yajun Zhang, Xiaodan Chong, Yanchun Meng, Jian Dong, Yirong Zhao and 9 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03698383 (Phase II Study of Trastuzumab Biosimilar), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03698383 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Phase II Study of Trastuzumab Biosimilar (Herzuma®) Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer Who Progressed After 2 or More HER-2 Directed Chemotherapy

TypeinterventionalSponsorKorean Cancer Study GroupRan2019 to 2021Enrolled15ConditionsHER2-positive Breast Cancer, Metastatic Breast CancerArmsTrastuzumab biosimilars(Herzuma), Gedatolisib
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Lingfei Wang *Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Xiaojie Yu *International Joint Cancer Institute, Second Military Medical University, Shanghai 200433, China.
Chao Wang *International Joint Cancer Institute, Second Military Medical University, Shanghai 200433, China.
Shujun Pan *Hangzhou Sanatorium of People's Liberation Army, Hangzhou 310007, China.
Beibei LiangShanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Yajun ZhangInternational Joint Cancer Institute, Second Military Medical University, Shanghai 200433, China.
Xiaodan ChongInternational Joint Cancer Institute, Second Military Medical University, Shanghai 200433, China.
Yanchun MengDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai 200032, China.
Jian DongDepartment of Vascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.
Yirong ZhaoInternational Joint Cancer Institute, Second Military Medical University, Shanghai 200433, China.
Yang YangInternational Joint Cancer Institute, Second Military Medical University, Shanghai 200433, China.
Huajing WangInternational Joint Cancer Institute, Second Military Medical University, Shanghai 200433, China.
Jie GaoDepartment of Pharmaceutical Sciences, Second Military Medical University, Shanghai 200433, China.
Huafeng WeiShanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Jian ZhaoShanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Hao WangInternational Joint Cancer Institute, Second Military Medical University, Shanghai 200433, China.
Chaohua HuDepartment of General Surgery, Xiaogan Central Hospital Affiliated to Wuhan University of Science and Technology, Wuhan 432000, China.
Wenze XiaoDepartment of Rheumatology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, China.
Bohua LiShanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China.
Second Military Medical University · CNShanghai University of Medicine and Health Sciences · CNFudan University · CNFudan University Shanghai Cancer Center · CNWuhan University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab, an anti-ErbB2 humanized antibody, brings benefit to patients with ErbB2-amplified metastatic breast cancers. However, the resistance to trastuzumab is common. Our previously reported H2-18, an anti-ErbB2 antibody, potently induced programmed cell death in trastuzumab-resistant breast cancer cells. Here, we aim to investigate the antitumor efficacy of H2-18 in combination with the pan-PI3K inhibitor GDC-0941 in trastuzumab-resistant breast cancer cell lines. The results showed that H2-18 and GDC-0941 synergistically inhibited the

Indexed as

anti-ErbB2 antibodybreast cancerGDC-0941programmed cell deathtrastuzumab resistance

Identifiers

PMID28881779
PMCPMC5581078
OpenAlexW2615035636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.